{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:56Z","timestamp":1785387596126,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ertugliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is approved for the glycemic management of patients with type 2 diabetes. Alstr\u00f6m syndrome (AS) is a rare autosomal recessive disorder caused by mutations in the ALMS1 gene, leading to ciliary dysfunction and multisystem involvement. AS is characterized by progressive neurosensory decline and metabolic disturbances, with symptoms such as retinal degeneration, which begins in childhood, sensorineural hearing loss, obesity, and cardiomyopathy. The 2020 European Alstr\u00f6m Syndrome Clinical Management Guidelines, developed by experts from various medical fields, offer evidence-based recommendations for managing these symptoms and improving the quality of life of affected individuals. Severe insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and renal failure significantly affect the quality of life and lifespan of patients with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of ertugliflozin in improving glycemic control, lipid metabolism, and insulin sensitivity in patients with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical data of two sibling with AS treated at the Department of Endocrinology in our hospital. Follow-up data were collected and analyzed to evaluate the efficacy and safety of ertugliflozin in patients with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During an 11-month observation period, ertugliflozin treatment exerted favorable effects on multiple metabolic parameters in the two patients. Glycemic control improved in both patients, as evidenced by significant reductions in HbA1c levels observed at 2 months. The homeostatic model assessment of insulin resistance (HOMA-IR) showed marked improvement in Patient 1. Patient 2 showed significant early improvement in HOMA-IR, but a rebound trend was observed later, potentially related to the inherent, rapidly progressive, severe insulin resistance characteristic of puberty in this patient. Further comprehensive evaluation is required to distinguish the long-term effects of SGLT2 inhibitors, such as ertugliflozin, from the progression of type 2 diabetes. Additionally, ertugliflozin demonstrated significant regulatory effects on lipid metabolism, and no adverse events occurred during the treatment period, indicating good safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Consistent with current clinical management guidelines for Alstr\u00f6m syndrome, ertugliflozin demonstrated clinically meaningful reductions in fasting and postprandial glucose concentrations in two patients with AS, as documented in this longitudinal case report. Modest improvements in total cholesterol levels were also observed; however, the isolated effect of ertugliflozin on triglycerides could not be ascertained in one patient due to concurrent fibrate therapy. Early enhancements in insulin sensitivity\u2014assessed via HOMA-IR and dynamic glucose tolerance testing\u2014were observed during the initial treatment phase; however, this effect waned over time in Patient 2, the younger patient. The agent was generally well tolerated, with no serious adverse events reported. Owing to the inherent limitations of this analysis\u2014including a small sample size (n = 2), absence of a control group, and lack of histopathological or mechanistic biomarker data\u2014these observations remain preliminary and warrant validation in adequately powered, prospective, controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1785257","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:47Z","timestamp":1785385307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Efficacy and safety of SGLT2 inhibitors in patients with Alstr\u00f6m syndrome: a follow-up report of two siblings from the same family"],"prefix":"10.3389","volume":"17","author":[{"given":"Bingjie","family":"Xue","sequence":"first","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailu","family":"Li","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Peng","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujun","family":"Fu","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","first-page":"1","article-title":"Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree","volume":"129","author":"Alstrom","year":"1959","journal-title":"Acta Psychiatr Neurol Scand Suppl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-020-01468-8","article-title":"Consensus clinical management guidelines for Alstr\u00f6m syndrome","volume":"15","author":"Tahani","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.16288\/j.yczz.22-217","article-title":"Diagnosis, treatment and genetic analysis of a case of Alstrom syndrome caused by compoud heterozygous mutation of ALMS1","volume":"44","author":"Yang","year":"2022","journal-title":"Yi Chuan"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.01952.x","article-title":"Hypertriglyceridaemia in Alstr\u00f6m's syndrome: causes and associations in 37 cases","volume":"60","author":"Paisey","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.5.1581","article-title":"Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes","volume":"54","author":"Hearn","year":"2005","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi235","article-title":"Alms1-disrupted mice recapitulate human Alstr\u00f6m syndrome","volume":"14","author":"Collin","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0647","article-title":"Relative adipose tissue failure in Alstr\u00f6m syndrome drives obesity-induced insulin resistance","volume":"70","author":"Geberhiwot","year":"2021","journal-title":"Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00496","article-title":"Comprehensive endocrine-metabolic evaluation of patients with Alstr\u00f6m syndrome compared with BMI-matched controls","volume":"103","author":"Han","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13163","article-title":"Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstr\u00f6m syndrome","volume":"36","author":"Gathercole","year":"2016","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.19538\/j.nk2024110101","article-title":"Endocrine and metabolic characteristics of Alstr\u00f6m syndrome","volume":"44","author":"Li","year":"2024","journal-title":"Chin J Pract Internal Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1399-5448.2011.00789.x","article-title":"The progression from obesity to type 2 diabetes in Alstr\u00f6m syndrome","volume":"13","author":"Bettini","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1871530321666210617164550","article-title":"Therapeutic interventions of novel SGLT2 inhibitors against metabolic disorders: transforming the association into perspectives","volume":"21","author":"Irshad","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the clinical pharmacology of Ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/0470862092.d0405","article-title":"Glucose toxicity","volume":"13","author":"Yki-J\u00e4rvinen","year":"1992","journal-title":"Endocr Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3390\/molecules30153112","article-title":"SGLT2 inhibitors: from molecular mechanisms to clinical outcomes in cardiology and diabetology","volume":"30","author":"Stielow","year":"2025","journal-title":"Molecules"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.752440","article-title":"Efficacy and safety of Ertugliflozin in type 2 diabetes: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Pharmacol Volume 12 - 2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.3390\/microorganisms13112442","article-title":"Evaluation of the oral microbiome in patients with Alstr\u00f6m and Bardet-Biedl syndromes and their heterozygous family members","volume":"13","author":"Zmys\u0142owska-Polakowska","year":"2025","journal-title":"Microorganisms"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01555-z","article-title":"Microbiota,\u00a0epidemiological and nutritional factors related to ketoacidosis at the onset of type 1 diabetes","volume":"57","author":"Rabbone","year":"2020","journal-title":"Acta Diabetol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: a narrative review","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"key":"B25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13098-025-01955-7","article-title":"Endocrine metabolism characteristics of Alstr\u00f6m syndrome in 25 Chinese patients and identification of a new splice site in the ALMS1 gene","volume":"17","author":"Peng","year":"2025","journal-title":"Diabetol Metab Syndr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:50Z","timestamp":1785385310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1785257"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1785257","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1785257"}}